Pliant Therapeutics 在针对原发性硬化性胆管炎患者的 2a 期临床试验中报告了 320 毫克贝索格斯特的积极安全性数据和抗纤维化作用。 Pliant Therapeutics reported positive safety data and antifibrotic effects for 320mg bexotegrast in a Phase 2a clinical trial for primary sclerosing cholangitis patients.
Pliant Therapeutics 宣布了贝索格斯特（320 mg）在其 2a 期临床试验 INTEGRIS-PSC 中的积极安全性数据，该试验针对原发性硬化性胆管炎和疑似肝纤维化患者。 Pliant Therapeutics announced positive safety data for bexotegrast (320 mg) in its Phase 2a clinical trial, INTEGRIS-PSC, for patients with primary sclerosing cholangitis and suspected liver fibrosis. Bexotegrast 在 12 周的治疗期间具有良好的耐受性，并且没有报告严重或严重的不良事件。 Bexotegrast was well-tolerated over a 12-week treatment period and no severe or serious adverse events were reported. 该治疗还显示出肝细胞功能和胆汁流量的改善。 The treatment also showed improvements in hepatocyte function and bile flow. 320 mg 剂量组表现出一致的抗纤维化作用，与之前的研究结果一致。 The 320 mg dose cohort demonstrated consistent antifibrotic effects in line with previous findings. 该公司将举办网络广播和电话会议，进一步讨论这些结果。 The company will host a webcast and conference call to discuss these results further.